The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...

Gifting allows recipients to access the article for free. AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, exceeded ...

AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer. AbbVie on Thursday said EvolveImmune will ...

AbbVie bumped earnings guidance higher following strong third-quarter sales as gains from the company's newer anti-inflammatory drugs offset expected declines from its former top dog, Humira. The ...

Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only until the question-and-answer portion of ...

In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $202.46, changing hands for $203.87/share. When a stock reaches the target an ...